29,700 Shares in Integra LifeSciences Holdings Corporation $IART Bought by Louisiana State Employees Retirement System

Louisiana State Employees Retirement System acquired a new stake in shares of Integra LifeSciences Holdings Corporation (NASDAQ:IART) during the 1st quarter, according to its most recent 13F filing with the SEC. The firm acquired 29,700 shares of the life sciences company’s stock, valued at approximately $280,000.

Several other institutional investors have also recently made changes to their positions in the company. Global Retirement Partners LLC bought a new stake in Integra LifeSciences in the 4th quarter worth about $25,000. Osaic Holdings Inc. grew its holdings in shares of Integra LifeSciences by 36.6% in the second quarter. Osaic Holdings Inc. now owns 4,119 shares of the life sciences company’s stock valued at $51,000 after acquiring an additional 1,104 shares in the last quarter. GAMMA Investing LLC increased its position in shares of Integra LifeSciences by 145.9% during the fourth quarter. GAMMA Investing LLC now owns 6,307 shares of the life sciences company’s stock valued at $78,000 after acquiring an additional 3,742 shares during the last quarter. Tower Research Capital LLC TRC lifted its holdings in Integra LifeSciences by 595.6% during the second quarter. Tower Research Capital LLC TRC now owns 7,958 shares of the life sciences company’s stock worth $98,000 after acquiring an additional 6,814 shares during the period. Finally, Virtu Financial LLC bought a new stake in Integra LifeSciences during the fourth quarter worth $124,000. Institutional investors own 84.78% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on IART shares. Citigroup restated a “neutral” rating and issued a $19.00 price objective (up from $16.00) on shares of Integra LifeSciences in a research note on Wednesday. BMO Capital Markets started coverage on Integra LifeSciences in a research note on Wednesday. They set a “market perform” rating and a $19.00 target price on the stock. Truist Financial reduced their price target on shares of Integra LifeSciences from $13.00 to $12.00 and set a “hold” rating for the company in a research report on Wednesday, April 15th. Argus upgraded shares of Integra LifeSciences from a “hold” rating to a “buy” rating and set a $25.00 price objective for the company in a report on Thursday, June 18th. Finally, Weiss Ratings raised shares of Integra LifeSciences from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, May 13th. One equities research analyst has rated the stock with a Buy rating, four have given a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Reduce” and an average target price of $17.17.

Integra LifeSciences Stock Up 6.3%

IART stock opened at $18.39 on Friday. The stock has a fifty day moving average of $16.15 and a 200-day moving average of $12.81. Integra LifeSciences Holdings Corporation has a fifty-two week low of $8.70 and a fifty-two week high of $18.92. The company has a market capitalization of $1.43 billion, a price-to-earnings ratio of -2.85, a PEG ratio of 1.20 and a beta of 1.22. The company has a debt-to-equity ratio of 1.75, a quick ratio of 1.95 and a current ratio of 3.38.

Integra LifeSciences (NASDAQ:IART) last announced its quarterly earnings data on Tuesday, May 5th. The life sciences company reported $0.54 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.41 by $0.13. The business had revenue of $391.92 million for the quarter, compared to analysts’ expectations of $381.81 million. Integra LifeSciences had a positive return on equity of 17.42% and a negative net margin of 30.15%.The firm’s quarterly revenue was up 2.4% compared to the same quarter last year. During the same period in the previous year, the business posted $0.41 EPS. Integra LifeSciences has set its FY 2026 guidance at 2.400-2.500 EPS and its Q2 2026 guidance at 0.440-0.520 EPS. As a group, equities research analysts predict that Integra LifeSciences Holdings Corporation will post 2.45 earnings per share for the current year.

Integra LifeSciences Company Profile

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.